AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
May 18 (Reuters) - Merck said on Monday its experimental drug helped certain patients with uterine cancer live longer and ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy, citing overhang from a new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck (MRK) in ...
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results